Schedule 13G ownership disclosure

4D Molecular Therapeutics Inc

Security class unavailable · CUSIP: 35104E100

Event date: 2022-06-16

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
Unavailable
Percent of class
6.6000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000921895-22-002049
Form type
SC 13G/A
Filer
4D Molecular Therapeutics, Inc.
CIK
CIK 1650648
Filed
Jun 21, 2022
Reporting period
Jun 16, 2022
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub